学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

赤松和土（アカマツワド）

研究テーマ	神経発生・多能性幹細胞
研究業績（論文）	2023年8月30日現在・原著 1. Akamatsu W, Okano HJ, Osumi N, Inoue T, Nakamura S, Sakakibara S, Miura M, Matsuo N, Darnell RB, Okano H: Mammalian ELAV-like neuronal RNA-binding proteins HuB and HuC promote neuronal development in both the central and the peripheral nervous systems. Proc Natl Acad Sci U S A. 96:9885-9890. 1999 2. Kawaguchi A, Miyata T, Sawamoto K, Takashita N, Murayama A, Akamatsu W, Ogawa M, Okabe M, Tano Y, Goldman SA, Okano H: Nestin-EGFP Transgenic Mice: Visualization of the Self-Renewal and Multipotency of CNS Stem Cells. Mol Cell Neurosci. 17:259-273, 2001 3. Akamatsu W, Fujihara H, Mitsuhashi T, Yano M, Shibata S, Hayakawa Y, Okano HJ, Sakakibara S, Takano H, Takano T, Takahashi T, Noda T, Okano H: The RNA-binding protein HuD regulates neuronal cell identity and maturation. Proc Natl Acad Sci U S A. 102:4625-4630, 2005 (赤松和土は責任著者) 4. Batista CM, Kippin TE, Willaime-Morawek S, Shimabukuro MK, Akamatsu W, van der Kooy D. A progressive and cell non-autonomous increase in striatal neural stem cells in the Huntington's disease R6/2 mouse. J Neurosci. 26:10452-10460, 2006 5. Akamatsu W, DeVeale B, Okano H, Cooney AJ, van der Kooy D: Suppression of Oct4 by germ cell nuclear factor restricts pluripotency and promotes neural stem cell development in the early neural lineage. J Neurosci. 29:2113-2124, 2009 (赤松和土は責任著者) 6. Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, Ohyama M, Amagai M, Matsuzaki Y, Yamanaka S, Okano H, Kawakami Y: Generation of human melanocytes from induced pluripotent stem cells. PLoS One. 6:e16182, 2011 7. Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N: Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet. 20:4530-4539, 2011 8. Lee EK, Kim W, Tominaga K, Martindale JL, Yang X, Subaran SS, Carlson OD, Mercken EM, Kulkarni RN, Akamatsu W, Okano H, Perrone-Bizzozero NI, de Cabo R, Egan JM, Gorospe M: RNA-binding protein HuD controls insulin translation. Mol Cell. 45:826-835, 2012 9. Matsui T, Takano M, Yoshida K, Ono S, Fujisaki C, Matsuzaki Y, Toyama Y, Nakamura M, Okano H, Akamatsu W: Neural stem cells directly differentiated from partially reprogrammed fibroblasts rapidly acquire gliogenic competency. Stem Cells. 30:1109-1119, 2012 (赤松和土は責任著者) 10. Yagi T, Kosakai A, Ito D, Okada Y, Akamatsu W, Nihei Y, Nabetani A, Ishikawa F, Arai Y, Hirose N, Okano H, Suzuki N: Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research. PLoS One. 7:e41572, 2012 11. Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, Nihira T, Kobayashi T, Ohyama M, Sato S, Takanashi M, Funayama M, Hirayama A, Soga T, Hishiki T, Suematsu M, Yagi T, Ito D, Kosakai A, Hayashi K, Shouji M, Nakanishi A, Suzuki N, Mizuno Y, Mizushima N, Amagai M, Uchiyama Y, Mochizuki H, Hattori N, Okano H: Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain. 5:35. 2012 12. Veraitch O, Kobayashi T, Imaizumi Y, Akamatsu W, Sasaki T, Yamanaka S, Amagai M, Okano H and Ohyama M: Human induced pluripotent stem cell-derived ectodermal precursor cells contribute to hair follicle morphogenesis in vivo. J Invest Dermatol. 133:1479-1488. 2013 13. Shofuda T, Kanematsu D, Fukusumi H, Yamamoto A, Bamba Y, Yoshitatsu S, Suemizu H, Nakamura M, Sugimoto Y, Furue MK, Kohara A, Akamatsu W, Okada Y, Okano H, Yamasaki M, Kanemura Y. Human Decidua-Derived Mesenchymal Cells Are a Promising Source for the Generation and Cell Banking of Human Induced Pluripotent Stem Cells. Cell Med. 4:125-47. 2012 14. Nihei Y, Ito D, Okada Y, Akamatsu W, Yagi T, Yoshizaki T, Okano H, Suzuki N: Enhanced Aggregation of Androgen Receptor in Induced Pluripotent Stem Cell-derived Neurons from Spinal and Bulbar Muscular Atrophy. J Biol Chem. 288: 8043-8052. 2013 15. Higurashi N, Uchida T, Christoph L, Misumi Y, Okada Y, Akamatsu W, Imaizumi Y, Zhang B, Nabeshima K, Mori M, Katsurabayashi S, Shirasaka S, Okano H and Hirose S: A human Dravet syndrome model from patient induced pluripotent stem cells. Mol Brain 6:19. 2013 16. Kim C, Kim W, Lee H, Ji E, Choe YJ, Martindale JL, Akamatsu W, Okano H, Kim HS, Nam SW, Gorospe M, Lee EK: The RNA binding protein, HuD regulates autophagosome formation in pancreatic β cells by promoting autophagy-related gene 5 expression. J Biol Chem. 289: 112-121. 2014 17. Bundo M, Toyoshima M, Ueda J, Nemoto-Miyake T, Sunaga F, Toritsuka M, Ikawa D, Kakita A, Okada Y, Akamatsu W, Kato M, Okano H, Kasai K, Kishimoto T, Nawa H, Yoshikawa T, Kato T, Iwamoto K: Increased Ll Retrotransposition in the neuronal genome in Schizophrenia. Neuron 81: 306-313. 2014 18. DeBoer E, Azevedo R, Vega T, Brodkin J, Akamatsu W, Okano H, Wagner G, Rasin MR. Prenatal deletion of the RNA binding protein HuD disrupts postnatal cortical circuit maturation and behavior. J Neurosci. 34:3674-86. 2014 19. Zhou Z, Kohda K, Ibata K, Kohyama J, Akamatsu W, Yuzaki M, Okano HJ, Sasaki E, Okano H. Reprogramming non-human primate somatic cells into functional neuronal cells by defined factors. Mol Brain. 7:24. 2014 20. Numasawa-Kuroiwa Y, Okada Y, Shibata S, Kishi N, Akamatsu W, Shoji M, Nakanishi A, Oyama M, Oasaka H, Inoue K, Takahashi K, Yamanaka S, Kosaki K, Takahashi T, Okano H. Involvement of ER Stress in Dysmyelination of Pelizaeu-Merzbacher Disease with PLP1 Missense Mutations Shown by iPSC-Derived Oligodendrocytes. Stem Cell Rep. 2:1-14. 2014 21. Yoshida T, Ozawa Y, Suzuki K, Yuki K, Ohyama M, Akamatsu W, Matsuzaki Y, Shimmura S, Mitani K, Tsubota K, Okano H. The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa. Mol Brain. 7:45. 2014 22. Maekawa M, Yamada K, Toyoshima M, Ohnishi T, Iwayama Y, Shimamoto C, Toyota T, Nozaki Y, Balan S, Matsuzaki H, Iwata Y, Suzuki K, Miyashita M, Kikuchi M, Kato M, Okada Y, Akamatsu W, Mori N, Owada Y, Itokawa M, Okano H, Yoshikawa T. Utility of Scalp Hair Follicles as a Novel Source of Biomarker Genes for Psychiatric Illnesses. Biol Psychiatry. 2015 Jul 15;78(2):116-25. 2015 23. Andoh-Noda T, Akamatsu W, Miyake K, Matsumoto T, Yamaguchi R, Sanosaka T, Okada Y, Kobayashi T, Ohyama M, Nakashima K, Kurosawa H, Kubota T, Okano H.　 Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage. Mol Brain. 8:31. 2015 (赤松和土は責任著者) 24. Ohta E, Nihira T, Uchino A, Imaizumi Y, Okada Y, Akamatsu W, Takahashi K, Hayakawa H, Nagai M, Ohyama M, Ryo M, Ogino M, Murayama S, Takashima A, Nishiyama K, Mizuno Y, Mochizuki H, Obata F, Okano H. I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway. Hum Mol Genet. 24:4879-900. 2015 25. Imaizumi K, Sone T, Ibata K, Fujimori K, Yuzaki M, Akamatsu W, Okano H. Controlling Regional Identity of hPSC-Derived Neurons to Uncover Neuronal Subtype Specificity of Neurological Disease Phenotypes Stem Cell Rep. 5:1010-22. 2015 (赤松和土は責任著者) 26. Maekawa M, Iwayama Y, Ohnishi T, Toyoshima M, Shimamoto C, Hisano Y, Toyota T, Balan S, Matsuzaki H, Iwata Y, Takagai S, Yamada K, Ota M, Fukuchi S, Okada Y, Akamatsu W, Tsujii M, Kojima N, Owada Y, Okano H, Mori N, Yoshikawa T. Investigation of the fatty acid transporter-encoding genes SLC27A3 and SLC27A4 in autism. Sci Rep. 5:16239. 2015 27. Matsumoto T, Fujimori K, Andoh-Noda T, Ando T, Kuzumaki N, Toyoshima M, Tada H, Imaizumi K, Ishikawa M, Yamaguchi R, Isoda M, Zhou Z, Sato S, Kobayashi T, Ohtaka M, Nishimura K, Kurosawa H, Yoshikawa T, Takahashi T, Nakanishi M, Ohyama M, Hattori N, Akamatsu W, Okano H. Functional Neurons Generated from T Cell-Derived Induced Pluripotent Stem Cells for Neurological Disease Modeling. Stem Cell Rep. 6:422-35. 2016 (赤松和土は責任著者) 28. Ichiyanagi N, Fujimori K, Yano M, Ishihara-Fujisaki C, Sone T, Akiyama T, Okada Y, Akamatsu W, Matsumoto T, Ishikawa M, Nishimoto Y, Ishihara Y, Sakuma T, Yamamoto T, Tsuiji H, Suzuki N, Warita H, Aoki M, Okano H. Establishment of In Vitro FUS-Associated Familial Amyotrophic Lateral Sclerosis Model Using Human Induced Pluripotent Stem Cells. Stem Cell Rep. 6:496-510. 2016 29. Ouchi T, Morikawa S, Shibata S, Fukuda K, Okuno H, Fujimura T, Kuroda T, Ohyama M, Akamatsu W, Nakagawa T, Okano H. LNGFR+THY-1+ human pluripotent stem cell-derived neural crest-like cells have the potential to develop into mesenchymal stem cells. Differentiation. 92:270-280. 2016 30. Bamba Y, Shofuda T, Kato M, Pooh RK, Tateishi Y, Takanashi J, Utsunomiya H, Sumida M, Kanematsu D, Suemizu H, Higuchi Y, Akamatsu W, Gallagher D, Miller FD, Yamasaki M, Kanemura Y, Okano H. In vitro characterization of neurite extension using induced pluripotent stem cells derived from lissencephaly patients with TUBA1A missense mutations. Mol Brain. 9:70. 2016 31. Fujimori K, Tezuka T, Ishiura H, Mitsui J, Doi K, Yoshimura J, Tada H, Matsumoto T, Isoda M, Hashimoto R, Hattori N, takahashi T, Morishita S, Tsuji S, Akamatsu W, Okano H.　Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines. Mol Brain. 9:88. 2016 32. Toyoshima M, Akamatsu W, Okada Y, Ohnishi T, Balan S, Hisano Y, Iwayama Y, Toyota T, Matsumoto T, Itasaka N, Sugiyama S, Tanaka M, Yano M, Dean B, Okano H, Yoshikawa T. Analysis of induced pluripotent stem cells carrying 22q11.2 deletion. Transl Psychiatry. 6:e934. 2016 33. Hoashi Y, Okamoto S, Abe Y, Matsumoto T, Tanaka J, Yoshida Y, Imaizumi K, Mishima K, Akamatsu W, Okano H, Baba K. Generation of neural cells using iPSCs from sleep bruxism patients with 5-HT2A polymorphism. J Prosthodont Res. Dec 1. pii: S1883-1958(16)30106-2. 2016 34. Okuno H, Nakabayashi K, Abe K, Ando T, Sanosaka T, Kohyama J, Akamatsu W, Ohyama M, Takahashi T, Kosaki K, Okano H. Changeability of the fully methylated status of the 15q11.2 region in induced pluripotent stem cells derived from a patient with Prader-Willi syndrome. Congenit Anom (Kyoto). 2016 [Epub ahead of print] 35. Hosoya M, Fujioka M, Sone T, Okamoto S, Akamatsu W, Ukai H, Ueda HR, Ogawa K, Matsunaga T, Okano H. Cochlear Cell Modeling Using Disease-Specific iPSCs Unveils a Degenerative Phenotype and Suggests Treatments for Congenital Progressive Hearing Loss. Cell Reports Jan 3;18(1):68-81. 2017 36. Suzuki S, Akamatsu W, Kisa F, Sone T, Ishikawa KI, Kuzumaki N, Katayama H, Miyawaki A, Hattori N, Okano H. Efficient induction of dopaminergic neuron differentiation from induced pluripotent stem cells reveals impaired mitophagy in PARK2 neurons. Biochem Biophys Res Commun. 483(1):88-93. 2017 (赤松和土は責任著者) 37. Andoh-Noda T, Akamatsu W, Miyake K, Kobayashi T, Ohyama M, Kurosawa H, Kubota T, Okano H. Differential X Chromosome Inactivation Patterns during the Propagation of Human Induced Pluripotent Stem Cells. Keio J Med. Jan 20. 2017 (赤松和土は責任著者) 38. Takayama Y, Wakabayashi T, Kushige H, Saito Y, Shibuya Y, Shibata S, Akamatsu W, Okano H, Kida YS. Brief exposure to small molecules allows induction of mouse embryonic fibroblasts into neural crest-like precursors. FEBS Lett. 591(4):590-602. 2017 39. Nakazawa T, Kikuchi M, Ishikawa M, Yamamori H, Nagayasu K, Matsumoto T, Fujimoto M, Yasuda Y, Fujiwara M, Okada S, Matsumura K, Kasai A, Hayata-Takano A, Shintani N, Numata S, Takuma K, Akamatsu W, Okano H, Nakaya A, Hashimoto H, Hashimoto R. Differential gene expression profiles in neurons generated from lymphoblastoid B-cell line-derived iPS cells from monozygotic twin cases with treatment-resistant schizophrenia and discordant responses to clozapine. Schizophr Res. 181:75-82. 2017 40.Shiba-Fukushima K, Ishikawa KI, Inoshita T, Izawa N, Takanashi M, Sato S, Onodera O, Akamatsu W, Okano H, Imai Y, Hattori N. Evidence that phosphorylated ubiquitin signaling is involved in the etiology of Parkinson's disease. Hum Mol Genet. 2017 May 25. doi: 10.1093/hmg/ddx201. [Epub ahead of print] 41.Fujimori K, Matsumoto T, Kisa F, Hattori N, Okano H, Akamatsu W. Escape from Pluripotency via Inhibition of TGF-β/BMP and Activation of Wnt Signaling Accelerates Differentiation and Aging in hPSC Progeny Cells.Stem Cell Reports. 2017 Nov 14;9(5):1675-1691. 42.Okuno H, Renault Mihara F, Ohta S, Fukuda K, Kurosawa K, Akamatsu.W, Sanosaka T, Kohyama J, Hayashi K, Nakajima K, Takahashi T, Wysocka J, Kosaki K, Okano H.CHARGE syndrome modeling using patient-iPSCs reveals defective migration of neural crest cells harboring CHD7 mutations.Elife. 2017 Nov 28;6. pii: e21114. 43.Mao D, Chung XKW, Andoh-Noda T, Qin Y, Sato SI, Takemoto Y, Akamatsu W, Okano H, Uesugi M. Chemical decontamination of iPS cell-derived neural cell mixtures.Chem Commun (Camb). 2018 Feb 1;54(11):1355-1358. 44,Suda Y, Kuzumaki N, Sone T, Narita M, Tanaka K, Hamada Y, Iwasawa C, Shibasaki M, Maekawa A, Matsuo M, Akamatsu W, Hattori N, Okano H, Narita M. Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson's disease-like motor dysfunction. Mol Brain. 2018 Feb 20;11(1):6 45.Imaizumi K, Fujimori K, Ishii S, Otomo A, Hosoi Y, Miyajima H, Warita H, Aoki M, Hadano S, Akamatsu W, Okano H. strocaudal Areal Patterning of Human PSC-Derived Cortical Neurons by FGF8 Signaling. eNeuro. 2018 Apr 26;5(2).(* Corresponding Author) 46.Ren Q, Ma M, Yang J, Nonaka R, Yamaguchi A, Ishikawa KI, Kobayashi K, Murayama S, Hwang SH, Saiki S, Akamatsu W, Hattori N, Hammock BD, Hashimoto K. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5815-E5823 47. Ueno SI, Saiki S, Fujimaki M, Takeshige-Amano H, Hatano T, Oyama G, Ishikawa KI, Yamaguchi A, Nojiri S, Akamatsu W, Hattori N. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease. Cells. 2018 Dec 29;8(1). 48. Nishihara K, Shiga T, Nakamura E, Akiyama T, Sasaki T, Suzuki S, Ko M, Tada N, Okano H, Akamatsu W. Induced pluripotent stem cells reprogrammed with three inhibitors show accelerated differentiation potentials and express 2-cell-stage markers. Stem Cell Reports 2019 Feb 12;12(2):305-318. 49.Tsunemi T, Perez-Rosello T, Ishiguro Y, Yoroisaka A, Jeon S, Hamada K, Rammonhan M, Wong YC, Xie Z, Akamatsu W, Mazzulli JR, Surmeier DJ, Hattori N, Krainc D.Increased Lysosomal Exocytosis Induced by Lysosomal Ca 2+ Channel Agonists Protects Human Dopaminergic Neurons From α-Synuclein Toxicity. J Neurosci. 2019 Jul 17;39(29):5760-5772. 50.Kuzumaki N, Suda Y, Iwasawa C, Narita M, Sone T, Watanabe M, Maekawa A, Matsumoto T, Akamatsu W, Igarashi K, Tamura H, Takeshima H, Tawfik VL, Ushijima T, Hattori N, Okano H, Narita M.Cell-specific Overexpression of COMT in Dopaminergic Neurons of Parkinson's Disease. Brain. 2019 Jun 1;142(6):1675-1689. 51.Hirano K, Fujimaki M, Sasazawa Y, Yamaguchi A, Ishikawa KI, Miyamoto K, Souma S, Furuya N, Imamichi Y, Yamada D, Saya H, Akamatsu W, Saiki S, Hattori N. Neuroprotective effects of memantine via enhancement of autophagy.Biochem Biophys Res Commun. 2019 Oct 8;518(1):161-170. 52.Ikeda A, Nishioka K, Meng H, Takanashi M, Hasegawa I, Inoshita T, Shiba-Fukushima K, Li Y, Yoshino H, Mori A, Okuzumi A, Yamaguchi A, Nonaka R, Izawa N, Ishikawa KI, Saiki H, Morita M, Hasegawa M, Hasegawa K, Elahi M, Funayama M, Okano H, Akamatsu W, Imai Y, Hattori N.Mutations in CHCHD2 cause α-synuclein aggregation.Hum Mol Genet. 2019 Dec 1;28(23):3895-3911. 53.Fukunaga I, Shiga T, Chen C, Oe Y, Danzaki K, Ohta S, Matsuoka R, Anzai T, Hibiya-Motegi R, Tajima S, Ikeda K, Akamatsu W, Kamiya K.Generation of the induced pluripotent stem cell (hiPSC) line (JUFMDOi004-A) from a patient with hearing loss carrying GJB2 (p.V37I) mutation. Stem Cell Res. 2020 Mar;43:101674. 54.Kataura T, Saiki S, Ishikawa KI, Akamatsu W, Sasazawa Y, Hattori N, Imoto M.BRUP-1, an intracellular bilirubin modulator, exerts neuroprotective activity in a cellular Parkinson's disease model. J Neurochem. 2020 Mar 3. 55. Oji Y, Hatano T, Ueno SI, Funayama M, Ishikawa KI, Okuzumi A, Noda S, Sato S, Satake W, Toda T, Li Y, Hino-Takai T, Kakuta S, Tsunemi T, Yoshino H, Nishioka K, Hattori T, Mizutani Y, Mutoh T, Yokochi F, Ichinose Y, Koh K, Shindo K, Takiyama Y, Hamaguchi T, Yamada M, Farrer MJ, Uchiyama Y, Akamatsu W, Wu YR, Matsuda J, Hattori N.Variants in saposin D domain of prosaposin gene linked to Parkinson's disease.Brain. 2020 Apr 1;143(4):1190-1205. 56.Popovitchenko T, Park Y, Page NF, Luo X, Krsnik Z, Liu Y, Salamon I, Stephenson JD, Kraushar ML, Volk NL, Patel SM, Wijeratne HRS, Li D, Suthar KS, Wach A, Sun M, Arnold SJ, Akamatsu W, Okano H, Paillard L, Zhang H, Buyske S, Kostovic I, De Rubeis S, Hart RP, Rasin MR.Translational derepression of Elavl4 isoforms at their alternative 5' UTRs determines neuronal development. Nat Commun. 2020 Apr 3;11(1):1674. 57.Shiba-Fukushima K, Inoshita T, Sano O, Iwata H, Ishikawa KI, Okano H, Akamatsu W, Imai Y, Hattori N.A Cell-Based High-Throughput Screening Identified Two Compounds that Enhance PINK1-Parkin Signaling. iScience. 2020 Apr 11;23(5):101048. 58.Yamaguchi A, Ishikawa KI, Inoshita T, Shiba-Fukushima K, Saiki S, Hatano T, Mori A, Oji Y, Okuzumi A, Li Y, Funayama M, Imai Y, Hattori N, Akamatsu W. Identifying Therapeutic Agents for Amelioration of Mitochondrial Clearance Disorder in Neurons of Familial Parkinson Disease. Stem Cell Reports . 2020 Jun 9;14(6):1060-1075. doi: 10.1016/j.stemcr.2020.04.011. 59.Fukunaga I, Shirai K, Oe Y, Danzaki K, Ohta S, Shiga T, Chen C, Ikeda K, Akamatsu W, Kawano A, Kamiya K. Generation of two induced pluripotent stem cell lines from PBMCs of siblings carrying c.235delC mutation in the GJB2 gene associated with sensorineural hearing loss.Stem Cell Res. 2020 Jul 19;47:101910. doi: 10.1016/j.scr.2020.101910. 60.Tsunemi T, Ishiguro Y, Yoroisaka A, Valdez C, Miyamoto K, Ishikawa K, Saiki S, Akamatsu W, Hattori N, Krainc D. Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation. J Neurosci . 2020 Nov 4;40(45):8618-8628. doi: 10.1523/JNEUROSCI.0954-20.2020. 61.Kano M, Takanashi M, Oyama G, Yoritaka A, Hatano T, Shiba-Fukushima K, Nagai M, Nishiyama K, Hasegawa K, Inoshita T, Ishikawa KI, Akamatsu W, Imai Y, Bolognin S, Schwamborn JC, Hattori N. Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations. NPJ Parkinsons Dis . 2020 Nov 13;6(1):33. doi: 10.1038/s41531-020-00137-8. 62.Yokota M, Kakuta S, Shiga T, Ishikawa KI, Okano H, Hattori N, Akamatsu W, Koike M. Establishment of an in vitro model for analyzing mitochondrial ultrastructure in PRKN-mutated patient iPSC-derived dopaminergic neurons. Mol Brain. 2021 Mar 23;14(1):58. doi: 10.1186/s13041-021-00771-0. 63.Fukunaga I, Oe Y, Danzaki K, Ohta S, Chen C, Iizumi M, Shiga T, Matsuoka R, Anzai T, Hibiya-Motegi R, Tajima S, Ikeda K, Akamatsu W, Kamiya K. Generation of two iPSC lines from siblings of a homozygous patient with hearing loss and a heterozygous carrier with normal hearing carrying p.G45E/Y136X mutation in GJB2. Stem Cell Res. 2021 May;53:102290. doi: 10.1016/j.scr.2021.102290. 64.Nakai K, Shiga T, Yasuhara R, Sarkar AK, Abe Y, Nakamura S, Hoashi Y, Kotani K, Tatsumoto S, Ishikawa H, Go Y, Inoue T, Mishima K, Akamatsu W, Baba K.In vitro monitoring of HTR2A-positive neurons derived from human-induced pluripotent stem cells. Sci Rep. 2021 Jul 29;11(1):15437. doi: 10.1038/s41598-021-95041-3. 65.Toritsuka M, Yoshino H, Makinodan M, Ikawa D, Kimoto S, Yamamuro K, Okamura K, Akamatsu W, Okada Y, Matsumoto T, Hashimoto K, Ogawa Y, Saito Y, Watanabe K, Aoki C, Takada R, Fukami SI, Hamano-Iwasa K, Okano H, Kishimoto T. Developmental dysregulation of excitatory-to-inhibitory GABA-polarity switch may underlie schizophrenia pathology: A monozygotic-twin discordant case analysis in human iPS cell-derived neurons. Neurochem Int. 2021 Nov;150:105179. 66.Yamaguchi A, Ishikawa KI, Akamatsu W. Methods to Induce Small-Scale Differentiation of iPS Cells into Dopaminergic Neurons and to Detect Disease Phenotypes. Methods Mol Biol. 2022;2549:271-279. 67.Ishikawa KI, Ishiguro M, Li Y, Nishioka K, Hattori N, Akamatsu W. Generation of three hiPSC clones from a Parkinson's disease patient with a heterozygous variant of VPS35 p.D620N. Stem Cell Res. 2022 Jan 3;59:102658. 68.Miyamoto K, Saiki S, Matsumoto H, Suzuki A, Yamashita Y, Iseki T, Ueno SI, Shiina K, Kataura T, Kamagata K, Imamichi Y, Sasazawa Y, Fujimaki M, Akamatsu W, Hattori N. Systemic Metabolic Alteration Dependent on the Thyroid-Liver Axis in Early PD. Ann Neurol. 2022 Sep 21. doi: 10.1002/ana.26510. 69.Sasaki R, Kurebayashi N, Eguchi H, Horimoto Y, Shiga T, Miyazaki S, Kashiyama T, Akamatsu W, Saito M. Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity Cancer Sci. 2022 Oct;113(10):3449-3462. 70.Ukaji T, Takahashi-Shibata M, Arai D, Tsutsumi H, Tajima S, Akamatsu W, Matsumoto F, Ikeda K, Usami SI, Kamiya K. Generation and characterization of a human iPSC line (JUFMDOi007-A) from a patient with Usher syndrome due to mutation in USH2A Stem Cell Res. 2023 Jun;69:103100. doi: 10.1016/j.scr.2023.103100. 71.Nakamura R, Nonaka R, Oyama G, Jo T, Kamo H, Nuermaimaiti M, Akamatsu W, Ishikawa KI, Hattori N. A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson's disease.Front Neurosci. 2023 Jul 12;17:1202027. doi: 10.3389/fnins.2023.1202027. eCollection 2023. 72.Torii S, Arakawa S, Sato S, Ishikawa KI, Taniguchi D, Sakurai HT, Honda S, Hiraoka Y, Ono M, Akamatsu W, Hattori N, Shimizu S.Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2.EMBO Mol Med. 2023 Aug 14:e17451. doi: 10.15252/emmm.202317451. 73. Yokota M, Yoshino Y, Hosoi M, Hashimoto R, Kakuta S, Shiga T, Ishikawa KI, Okano H, Hattori N, Akamatsu W, Koike M. Reduced ER-mitochondrial contact sites and mitochondrial Ca2+ flux in PRKN-mutant patient tyrosine hydroxylase reporter iPSC lines. Front Cell Dev Biol. 2023 Sep 8;11:1171440. doi: 10.3389/fcell.2023.1171440. eCollection 2023. 74. Daida K, Funayama M, Billingsley KJ, Malik L, Miano-Burkhardt A, Leonard HL, Makarious MB, Iwaki H, Ding J, Gibbs JR, Ishiguro M, Yoshino H, Ogaki K, Oyama G, Nishioka K, Nonaka R, Akamatsu W, Blauwendraat C, Hattori N. Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease. Mov Disord. 2023 Dec;38(12):2249-2257. 75. Ishikawa KI, Shiga T, Funayama M, Hattori N, Akamatsu W. Generation of a control iPS cell line (JUCGRMi005-A) with no abnormalities in Parkinson's disease-related genes. Stem Cell Res. 2024 Feb:74:103271. 76. Ishikawa KI, Shiga T, Funayama M, Hattori N, Akamatsu W. Generation of a control iPS cell line (JUCGRMi006-A) with no abnormalities in Parkinson's disease-related genes. Stem Cell Res. 2024 Feb:74:103270. 77. Liu L, Yang J, Otani Y, Shiga T, Yamaguchi A, Oda Y, Hattori M, Goto T, Ishibashi S, Kawashima-Sonoyama Y, Ishihara T, Matsuzaki Y, Akamatsu W, Fujitani M, Taketani T. MELAS-Derived Neurons Functionally Improve by Mitochondrial Transfer from Highly Purified Mesenchymal Stem Cells (REC) Int J Mol Sci 2023 Dec 6;24(24):17186. doi: 10.3390/ijms242417186. 78. Ishikawa KI, Shiga T, Yoshino H, Nishioka K, Hattori N, Akamatsu W. Generation of three clones (JUCGRMi002-A, B, C) of induced pluripotent stem cells from a Parkinson's disease patient with SNCA duplication. Stem Cell Res. 2024 Feb;74:103296. 79. Ishikawa KI, Okuzumi A, Yoshino H, Hattori N, Akamatsu W. Generation of hiPSCs (JUCGRMi003-A) from a patient with Parkinson's disease with PARK2 mutation Stem Cell Res 2024 Apr:76:103323. doi: 10.1016/j.scr.2024.103323. Epub 2024 Jan 30. 80.Liu X, Ishikawa KI, Hattori N, Akamatsu W. Generation of one induced pluripotent stem cell line JUCGRMi004-A from a Charcot-Marie-Tooth disease type 1A (CMT1A) patient with PMP22 duplication Stem Cell Res . 2024 Jun:77:103401. doi: 10.1016/j.scr.2024.103401. Epub 2024 Mar 24. 81.Hori A, Inaba H, Hato T, Tanaka K, Sato S, Okamoto M, Horiuchi Y, Paran FJ, Tabe Y, Mori S, Rosales C, Akamatsu W, Murayama T, Kurebayashi N, Sakurai T, Ai T, Miida T. Carvedilol suppresses ryanodine receptor-dependent Ca2+ bursts in human neurons bearing PSEN1 variants found in early onset Alzheimer's disease PLoS One. 2024 Aug 22;19(8):e0291887. doi: 10.1371/journal.pone.0291887. eCollection 2024. 82.Arai D, Takahashi-Shibata M, Ukaji T, Tsutsumi H, Tajima S, Nishio SY, Ishikawa KI, Akamatsu W, Matsumoto F, Ikeda K, Usami SI, Kamiya K. Generation of an induced pluripotent stem cell line from a late-onset, progressive high frequency hearing loss patient due to mutation in CDH23 Stem Cell Res. 2024 Sep;79:103471. doi: 10.1016/j.scr.2024.103471. Epub 2024 Jun 12. ・和文総説 1) 岡野　栄之, 榊原　伸一, 今井　貴雄, 赤松　和土神経発生の新しい制御因子の発見とその臨床応用への試み：脳の科学　20: 665-670 1998 2) 赤松　和土, 岡野　栄之：神経特異的RNA結合蛋白質による神経発生の制御.　蛋白質・核酸・酵素　: 45(3) 19-24 ,2000 3) 赤松　和土, 岡野　栄之：神経幹細胞の分化制御機構と再生医学への応用：医学のあゆみ　: 192(8) 843-846 ,2000 4) 赤松　和土, 岡野　栄之：神経幹細胞の分化制御機構と再生医学への応用」：臨床リハビリテーション :2000 9:811 5) 赤松　和土, 岡野　栄之：神経幹細胞とその神経疾患治療への応用：脳と発達: 2001 33;114-120 6) 赤松　和土：神経特異的RNA結合蛋白質による神経発生の制御：小児科診療　2001,64(12);2228-2229 7) 赤松　和土：神経幹細胞とその神経疾患治療への応用：小児科: 42(13);2039-2045　2001 8) 今井貴雄，岡部正隆，赤松和土，岡野ジェイムス洋尚，岡野栄之: 神経分化を制御する神経系特異的RNA結合蛋白質: 生体の科学 V.53/No.2/P.84-90 ; 2002 9) 松井　健, 赤松　和土, 岡野栄之: 神経を創る─ Direct conversion による神経系細胞の誘導と医薬応用, in vivo実験医学によるヒト疾患解明の最前線実験医学増刊号 30(2) 43-50, 2012 10) 赤松　和土：疾患特異的iPS細胞研究の基礎と実際：バイオクリニカ　28(3) 22-26　2013 11) 赤松　和土：神経系のiPS technologyの今後の展望：神経内科検査のみかた−脳のイメージングを中心に：モダンフィジシャン　33(5) 696-698 2013 12) 赤松　和土：神経幹細胞の分化誘導・直接誘導実験医学増刊　Vol.33 No.2 再生医療2015 幹細胞と疾患iPS細胞の研究最前線 13) 赤松　和土：線維芽細胞→神経幹細胞　細胞工学別冊『ダイレクトリプログラミング』2015 14) 赤松　和土：体細胞からの神経系細胞の直接誘導　日本臨床　2015　増刊号　 15) 石川景一、服部信孝、赤松和土: 疾患モデル細胞, iPS細胞を用いた毒性評価と創薬研究, iPS細胞を用いたパーキンソン病の病態解析日本臨牀　2015年6月増刊号 16) 赤松　和土：疾患特異的iPS細胞を用いた神経疾患研究：実験医学　34: 524-233, 2016 17) 赤松　和土：iPS細胞を用いた神経・精神疾患の研究：分子精神医学　16: 227-233, 2016 18) 赤松　和土：ヒト多能性幹細胞から脳・脊髄の任意領域のニューロンへの誘導技術：医学のあゆみ　259: 1148-1149, 2016.12.10 19) 赤松　和土：iPS細胞を用いた難病研究：LiSA　26(7): 687-694, 2019 20) 赤松　和土：iPS細胞を用いた神経疾患と創薬：月刊　腎臓内科　12（3）: 1−8, 2020 21) 赤松　和土：iPS細胞を用いたパーキンソン病の病態解析：生体の科学　73（5）: 484−485, 2022 22) 赤松　和土：iPS細胞を用いたパーキンソン病の病態解明と創薬：心身医学　63: 317−320, 2023 23) 赤松　和土：パーキンソン病の病態解明と創薬：分子精神医学　50（2）: 71−74, 2024 （英文総説） 1. Matsui T, Akamatsu W, Nakamura M, Okano H. Regeneration of the damaged central nervous system through reprogramming technology: Basic concepts and potential application for cell replacement therapy. Exp Neurol. 2012 Oct 1. doi:pii: S0014-4886(12)00378-0. 10.1016/j.expneurol.2012.09.016. 2. Andoh-Noda T, Inouye MO, Miyake K, Kubota T, Okano H, Akamatsu W. Modeling Rett Syndrome Using Human Induced Pluripotent Stem Cells. CNS Neurol Disord Drug Targets. 15:544-50. 2016 （英文著書） 1. The regulatory mechanisms of Neural Development: Roles of Cell-autonomous Cues in Cell-Fate Decisions. Keio University Symposia for LifeScience and Medicine, Vol2 Neural Development. Okano H., Kaneko Y., Nakamura Y., Akamatsu W., Yuasa Y., Imai T., Hirota Y., Jin MH., Tabuchi K., Taguchi A., Okabe M., Sakakibara S., Goto T., Uchiyama Y and Sawamoto K.：Springer-Verlag Tokyo 9-23,1999 2. Functions of neural RNA-binding proteins Musashi and Hu in stem cells and neuronal differentiation. RNA Binding Proteins in Development and Disease: Kawahara H, Yano M, Imai T, Akamatsu W, Okano HJ, Okano H: Research Signpost, 2007 3. Imamura M, Okuno H, Tomioka I, Kawamura Y, Lin ZY, Nakajima R, Akamatsu W, Okano HJ, Matsuzaki Y, Sasaki E, Okano H： Derivation of induced pluripotent stem cells by retroviral gene transduction in mammalian species. Methods Mol Biol. 925: 21-48. 2012 4. Ohta S, Imaizumi Y, Akamatsu W, Okano H, Kawakami Y: Generation of human melanocytes from induced pluripotent stem cells. Methods Mol Biol. 989: 193-215. 2013, 5. Direct Induction of Neural Stem Cells from Somatic Cells. Akamatsu W, Okano H. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease, Fifth Edition 2014 6. Ishikawa KI, Yamaguchi A, Okano H, Akamatsu W. Assessment of Mitophagy in iPS Cell-Derived Neurons. Methods Mol Biol. 2017 Mar 22. [Epub ahead of print] , 7. Yamaguchi A, Ishikawa KI, Akamatsu W. Methods to Induce Small-Scale Differentiation of iPS Cells into Dopaminergic Neurons and to Detect Disease Phenotypes. Methods Mol Biol. 2021 Mar 24. doi: 10.1007/7651_2021_376. 8. Ishikawa KI, Nonaka R, Akamatsu W. Differentiation of Midbrain Dopaminergic Neurons from Human iPS Cells. Methods Mol Biol. 2021;2322:73-80. doi: 10.1007/978-1-0716-1495-2_8. （和文著書） 1. 赤松和土、岡野栄之「神経系におけるRNA結合蛋白質を介した遺伝子発現調節機構」 RNAがわかる;羊土社　東京　125-130　2003 2. 赤松和土、岡野栄之「神経幹細胞とその神経疾患治療への応用」疾患モデル動物文光堂東京 2004 (アウトリーチ活動) 1. 赤松和土　「iPS細胞を使って神経系の病気に苦しむ患者さんを助けられるか？」　順天堂大学医学部　基礎研究医養成プログラム主催　高校生のための夏休み医学教室：研究医とのサイエンストーク2016.7.26 2. 赤松和土「iPS細胞を用いたパーキンソン病の病態研究と治療法開発」　「患者・社会と考える再生医療」～「再生医療の研究をめぐる情報」について、みんなで考えてみませんか？～日本再生医療学会イベント（大阪）　2018.1.28 3. 赤松和土「iPS細胞を使って脳の病気を再現する—病気の仕組みの解明と新しい薬の開発—」　順天堂大学第41回都民公開講座「再生医療の現状」　2018.2.17 (プレスリリース) 1.2016年2月19日順天堂大学ヒトiPS 細胞の高効率な神経分化誘導方法の開発とパーキンソン病iPS細胞バンクの構築へ　～パーキンソン病の病態研究・再生医療を促進～ 2.2017年10月27日順天堂大学 3つの小分子化合物を用いてヒトiPS細胞の分化能力を促進する基盤技術を開発～～病態モデルにおける分化成熟・老化を促進、iPS細胞株選別を不要に～ 3. 2019年2月1日順天堂大学 3つの化合物を用いてiPS細胞の分化成熟能力を高める技術を開発～成熟した細胞への分化誘導期間を短縮～ 4. 2020年5月29日順天堂大学パーキンソン病の病態を改善させる治療薬探索システムを確立～患者由来iPS細胞を用いた薬剤スクリーニングシステム～

研究テーマ

神経発生・多能性幹細胞

研究業績（論文）

2023年8月30日現在

・原著
1. Akamatsu W, Okano HJ, Osumi N, Inoue T, Nakamura S, Sakakibara S, Miura M, Matsuo N, Darnell RB, Okano H: Mammalian ELAV-like neuronal RNA-binding proteins HuB and HuC promote neuronal development in both the central and the peripheral nervous systems. Proc Natl Acad Sci U S A. 96:9885-9890. 1999

2. Kawaguchi A, Miyata T, Sawamoto K, Takashita N, Murayama A, Akamatsu W, Ogawa M, Okabe M, Tano Y, Goldman SA, Okano H: Nestin-EGFP Transgenic Mice: Visualization of the Self-Renewal and Multipotency of CNS Stem Cells. Mol Cell Neurosci. 17:259-273, 2001

3. Akamatsu W, Fujihara H, Mitsuhashi T, Yano M, Shibata S, Hayakawa Y, Okano HJ, Sakakibara S, Takano H, Takano T, Takahashi T, Noda T, Okano H: The RNA-binding protein HuD regulates neuronal cell identity and maturation. Proc Natl Acad Sci U S A. 102:4625-4630, 2005 (赤松和土は責任著者)

4. Batista CM, Kippin TE, Willaime-Morawek S, Shimabukuro MK, Akamatsu W, van der Kooy D. A progressive and cell non-autonomous increase in striatal neural stem cells in the Huntington's disease R6/2 mouse. J Neurosci. 26:10452-10460, 2006

5. Akamatsu W, DeVeale B, Okano H, Cooney AJ, van der Kooy D: Suppression of Oct4 by germ cell nuclear factor restricts pluripotency and promotes neural stem cell development in the early neural lineage. J Neurosci. 29:2113-2124, 2009 (赤松和土は責任著者)

6. Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, Ohyama M, Amagai M, Matsuzaki Y, Yamanaka S, Okano H, Kawakami Y: Generation of human melanocytes from induced pluripotent stem cells. PLoS One. 6:e16182, 2011

7. Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N: Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet. 20:4530-4539, 2011

8. Lee EK, Kim W, Tominaga K, Martindale JL, Yang X, Subaran SS, Carlson OD, Mercken EM, Kulkarni RN, Akamatsu W, Okano H, Perrone-Bizzozero NI, de Cabo R, Egan JM, Gorospe M: RNA-binding protein HuD controls insulin translation. Mol Cell. 45:826-835, 2012

9. Matsui T, Takano M, Yoshida K, Ono S, Fujisaki C, Matsuzaki Y, Toyama Y, Nakamura M, Okano H, Akamatsu W: Neural stem cells directly differentiated from partially reprogrammed fibroblasts rapidly acquire gliogenic competency. Stem Cells. 30:1109-1119, 2012 (赤松和土は責任著者)

10. Yagi T, Kosakai A, Ito D, Okada Y, Akamatsu W, Nihei Y, Nabetani A, Ishikawa F, Arai Y, Hirose N, Okano H, Suzuki N: Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research. PLoS One. 7:e41572, 2012

11. Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, Nihira T, Kobayashi T, Ohyama M, Sato S, Takanashi M, Funayama M, Hirayama A, Soga T, Hishiki T, Suematsu M, Yagi T, Ito D, Kosakai A, Hayashi K, Shouji M, Nakanishi A, Suzuki N, Mizuno Y, Mizushima N, Amagai M, Uchiyama Y, Mochizuki H, Hattori N, Okano H: Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain. 5:35. 2012

12. Veraitch O, Kobayashi T, Imaizumi Y, Akamatsu W, Sasaki T, Yamanaka S, Amagai M, Okano H and Ohyama M: Human induced pluripotent stem cell-derived ectodermal precursor cells contribute to hair follicle morphogenesis in vivo. J Invest Dermatol. 133:1479-1488. 2013

13. Shofuda T, Kanematsu D, Fukusumi H, Yamamoto A, Bamba Y, Yoshitatsu S, Suemizu H, Nakamura M, Sugimoto Y, Furue MK, Kohara A, Akamatsu W, Okada Y, Okano H, Yamasaki M, Kanemura Y. Human Decidua-Derived Mesenchymal Cells Are a Promising Source for the Generation and Cell Banking of Human Induced Pluripotent Stem Cells. Cell Med. 4:125-47. 2012

14. Nihei Y, Ito D, Okada Y, Akamatsu W, Yagi T, Yoshizaki T, Okano H, Suzuki N: Enhanced Aggregation of Androgen Receptor in Induced Pluripotent Stem Cell-derived Neurons from Spinal and Bulbar Muscular Atrophy. J Biol Chem. 288: 8043-8052. 2013

15. Higurashi N, Uchida T, Christoph L, Misumi Y, Okada Y, Akamatsu W, Imaizumi Y, Zhang B, Nabeshima K, Mori M, Katsurabayashi S, Shirasaka S, Okano H and Hirose S: A human Dravet syndrome model from patient induced pluripotent stem cells. Mol Brain 6:19. 2013

16. Kim C, Kim W, Lee H, Ji E, Choe YJ, Martindale JL, Akamatsu W, Okano H, Kim HS, Nam SW, Gorospe M, Lee EK: The RNA binding protein, HuD regulates autophagosome formation in pancreatic β cells by promoting autophagy-related gene 5 expression. J Biol Chem. 289: 112-121. 2014

17. Bundo M, Toyoshima M, Ueda J, Nemoto-Miyake T, Sunaga F, Toritsuka M, Ikawa D, Kakita A, Okada Y, Akamatsu W, Kato M, Okano H, Kasai K, Kishimoto T, Nawa H, Yoshikawa T, Kato T, Iwamoto K: Increased Ll Retrotransposition in the neuronal genome in Schizophrenia. Neuron 81: 306-313. 2014

18. DeBoer E, Azevedo R, Vega T, Brodkin J, Akamatsu W, Okano H, Wagner G, Rasin MR. Prenatal deletion of the RNA binding protein HuD disrupts postnatal cortical circuit maturation and behavior. J Neurosci. 34:3674-86. 2014

19. Zhou Z, Kohda K, Ibata K, Kohyama J, Akamatsu W, Yuzaki M, Okano HJ, Sasaki E, Okano H. Reprogramming non-human primate somatic cells into functional neuronal cells by defined factors. Mol Brain. 7:24. 2014

20. Numasawa-Kuroiwa Y, Okada Y, Shibata S, Kishi N, Akamatsu W, Shoji M, Nakanishi A, Oyama M, Oasaka H, Inoue K, Takahashi K, Yamanaka S, Kosaki K, Takahashi T, Okano H. Involvement of ER Stress in Dysmyelination of Pelizaeu-Merzbacher Disease with PLP1 Missense Mutations Shown by iPSC-Derived Oligodendrocytes. Stem Cell Rep. 2:1-14. 2014

21. Yoshida T, Ozawa Y, Suzuki K, Yuki K, Ohyama M, Akamatsu W, Matsuzaki Y, Shimmura S, Mitani K, Tsubota K, Okano H. The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa. Mol Brain. 7:45. 2014

22. Maekawa M, Yamada K, Toyoshima M, Ohnishi T, Iwayama Y, Shimamoto C, Toyota T, Nozaki Y, Balan S, Matsuzaki H, Iwata Y, Suzuki K, Miyashita M, Kikuchi M, Kato M, Okada Y, Akamatsu W, Mori N, Owada Y, Itokawa M, Okano H, Yoshikawa T. Utility of Scalp Hair Follicles as a Novel Source of Biomarker Genes for Psychiatric Illnesses. Biol Psychiatry. 2015 Jul 15;78(2):116-25. 2015

23. Andoh-Noda T, Akamatsu W, Miyake K, Matsumoto T, Yamaguchi R, Sanosaka T, Okada Y, Kobayashi T, Ohyama M, Nakashima K, Kurosawa H, Kubota T, Okano H.　 Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage. Mol Brain. 8:31. 2015 (赤松和土は責任著者)

24. Ohta E, Nihira T, Uchino A, Imaizumi Y, Okada Y, Akamatsu W, Takahashi K, Hayakawa H, Nagai M, Ohyama M, Ryo M, Ogino M, Murayama S, Takashima A, Nishiyama K, Mizuno Y, Mochizuki H, Obata F, Okano H. I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway. Hum Mol Genet. 24:4879-900. 2015

25. Imaizumi K, Sone T, Ibata K, Fujimori K, Yuzaki M, Akamatsu W, Okano H. Controlling Regional Identity of hPSC-Derived Neurons to Uncover Neuronal Subtype Specificity of Neurological Disease Phenotypes Stem Cell Rep. 5:1010-22. 2015 (赤松和土は責任著者)

26. Maekawa M, Iwayama Y, Ohnishi T, Toyoshima M, Shimamoto C, Hisano Y, Toyota T, Balan S, Matsuzaki H, Iwata Y, Takagai S, Yamada K, Ota M, Fukuchi S, Okada Y, Akamatsu W, Tsujii M, Kojima N, Owada Y, Okano H, Mori N, Yoshikawa T. Investigation of the fatty acid transporter-encoding genes SLC27A3 and SLC27A4 in autism. Sci Rep. 5:16239. 2015

27. Matsumoto T, Fujimori K, Andoh-Noda T, Ando T, Kuzumaki N, Toyoshima M, Tada H, Imaizumi K, Ishikawa M, Yamaguchi R, Isoda M, Zhou Z, Sato S, Kobayashi T, Ohtaka M, Nishimura K, Kurosawa H, Yoshikawa T, Takahashi T, Nakanishi M, Ohyama M, Hattori N, Akamatsu W, Okano H. Functional Neurons Generated from T Cell-Derived Induced Pluripotent Stem Cells for Neurological Disease Modeling. Stem Cell Rep. 6:422-35. 2016 (赤松和土は責任著者)

28. Ichiyanagi N, Fujimori K, Yano M, Ishihara-Fujisaki C, Sone T, Akiyama T, Okada Y, Akamatsu W, Matsumoto T, Ishikawa M, Nishimoto Y, Ishihara Y, Sakuma T, Yamamoto T, Tsuiji H, Suzuki N, Warita H, Aoki M, Okano H. Establishment of In Vitro FUS-Associated Familial Amyotrophic Lateral Sclerosis Model Using Human Induced Pluripotent Stem Cells. Stem Cell Rep. 6:496-510. 2016

29. Ouchi T, Morikawa S, Shibata S, Fukuda K, Okuno H, Fujimura T, Kuroda T, Ohyama M, Akamatsu W, Nakagawa T, Okano H. LNGFR+THY-1+ human pluripotent stem cell-derived neural crest-like cells have the potential to develop into mesenchymal stem cells. Differentiation. 92:270-280. 2016

30. Bamba Y, Shofuda T, Kato M, Pooh RK, Tateishi Y, Takanashi J, Utsunomiya H, Sumida M, Kanematsu D, Suemizu H, Higuchi Y, Akamatsu W, Gallagher D, Miller FD, Yamasaki M, Kanemura Y, Okano H. In vitro characterization of neurite extension using induced pluripotent stem cells derived from lissencephaly patients with TUBA1A missense mutations. Mol Brain. 9:70. 2016

31. Fujimori K, Tezuka T, Ishiura H, Mitsui J, Doi K, Yoshimura J, Tada H, Matsumoto T, Isoda M, Hashimoto R, Hattori N, takahashi T, Morishita S, Tsuji S, Akamatsu W, Okano H.　Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines. Mol Brain. 9:88. 2016

32. Toyoshima M, Akamatsu W, Okada Y, Ohnishi T, Balan S, Hisano Y, Iwayama Y, Toyota T, Matsumoto T, Itasaka N, Sugiyama S, Tanaka M, Yano M, Dean B, Okano H, Yoshikawa T. Analysis of induced pluripotent stem cells carrying 22q11.2 deletion. Transl Psychiatry. 6:e934. 2016

33. Hoashi Y, Okamoto S, Abe Y, Matsumoto T, Tanaka J, Yoshida Y, Imaizumi K, Mishima K, Akamatsu W, Okano H, Baba K. Generation of neural cells using iPSCs from sleep bruxism patients with 5-HT2A polymorphism. J Prosthodont Res. Dec 1. pii: S1883-1958(16)30106-2. 2016

34. Okuno H, Nakabayashi K, Abe K, Ando T, Sanosaka T, Kohyama J, Akamatsu W, Ohyama M, Takahashi T, Kosaki K, Okano H. Changeability of the fully methylated status of the 15q11.2 region in induced pluripotent stem cells derived from a patient with Prader-Willi syndrome. Congenit Anom (Kyoto). 2016 [Epub ahead of print]

35. Hosoya M, Fujioka M, Sone T, Okamoto S, Akamatsu W, Ukai H, Ueda HR, Ogawa K, Matsunaga T, Okano H. Cochlear Cell Modeling Using Disease-Specific iPSCs Unveils a Degenerative Phenotype and Suggests Treatments for Congenital Progressive Hearing Loss. Cell Reports Jan 3;18(1):68-81. 2017

36. Suzuki S, Akamatsu W, Kisa F, Sone T, Ishikawa KI, Kuzumaki N, Katayama H, Miyawaki A, Hattori N, Okano H. Efficient induction of dopaminergic neuron differentiation from induced pluripotent stem cells reveals impaired mitophagy in PARK2 neurons. Biochem Biophys Res Commun. 483(1):88-93. 2017 (赤松和土は責任著者)

37. Andoh-Noda T, Akamatsu W, Miyake K, Kobayashi T, Ohyama M, Kurosawa H, Kubota T, Okano H. Differential X Chromosome Inactivation Patterns during the Propagation of Human Induced Pluripotent Stem Cells. Keio J Med. Jan 20. 2017 (赤松和土は責任著者)

38. Takayama Y, Wakabayashi T, Kushige H, Saito Y, Shibuya Y, Shibata S, Akamatsu W, Okano H, Kida YS. Brief exposure to small molecules allows induction of mouse embryonic fibroblasts into neural crest-like precursors. FEBS Lett. 591(4):590-602. 2017

39. Nakazawa T, Kikuchi M, Ishikawa M, Yamamori H, Nagayasu K, Matsumoto T, Fujimoto M, Yasuda Y, Fujiwara M, Okada S, Matsumura K, Kasai A, Hayata-Takano A, Shintani N, Numata S, Takuma K, Akamatsu W, Okano H, Nakaya A, Hashimoto H, Hashimoto R. Differential gene expression profiles in neurons generated from lymphoblastoid B-cell line-derived iPS cells from monozygotic twin cases with treatment-resistant schizophrenia and discordant responses to clozapine. Schizophr Res. 181:75-82. 2017

40.Shiba-Fukushima K, Ishikawa KI, Inoshita T, Izawa N, Takanashi M, Sato S, Onodera O, Akamatsu W, Okano H, Imai Y, Hattori N. Evidence that phosphorylated ubiquitin signaling is involved in the etiology of Parkinson's disease. Hum Mol Genet. 2017 May 25. doi: 10.1093/hmg/ddx201. [Epub ahead of print]

41.Fujimori K, Matsumoto T, Kisa F, Hattori N, Okano H, Akamatsu W. Escape from Pluripotency via Inhibition of TGF-β/BMP and Activation of Wnt Signaling Accelerates Differentiation and Aging in hPSC Progeny Cells.Stem Cell Reports. 2017 Nov 14;9(5):1675-1691.

42.Okuno H, Renault Mihara F, Ohta S, Fukuda K, Kurosawa K, Akamatsu.W, Sanosaka T, Kohyama J, Hayashi K, Nakajima K, Takahashi T, Wysocka J, Kosaki K, Okano H.CHARGE syndrome modeling using patient-iPSCs reveals defective migration of neural crest cells harboring CHD7 mutations.Elife. 2017 Nov 28;6. pii: e21114.

43.Mao D, Chung XKW, Andoh-Noda T, Qin Y, Sato SI, Takemoto Y, Akamatsu W, Okano H, Uesugi M. Chemical decontamination of iPS cell-derived neural cell mixtures.Chem Commun (Camb). 2018 Feb 1;54(11):1355-1358.

44,Suda Y, Kuzumaki N, Sone T, Narita M, Tanaka K, Hamada Y, Iwasawa C, Shibasaki M, Maekawa A, Matsuo M, Akamatsu W, Hattori N, Okano H, Narita M. Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson's disease-like motor dysfunction. Mol Brain. 2018 Feb 20;11(1):6

45.Imaizumi K, Fujimori K, Ishii S, Otomo A, Hosoi Y, Miyajima H, Warita H, Aoki M, Hadano S, Akamatsu W*, Okano H*. strocaudal Areal Patterning of Human PSC-Derived Cortical Neurons by FGF8 Signaling. eNeuro. 2018 Apr 26;5(2).(* Corresponding Author)

46.Ren Q, Ma M, Yang J, Nonaka R, Yamaguchi A, Ishikawa KI, Kobayashi K, Murayama S, Hwang SH, Saiki S, Akamatsu W, Hattori N, Hammock BD, Hashimoto K. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5815-E5823

47. Ueno SI, Saiki S, Fujimaki M, Takeshige-Amano H, Hatano T, Oyama G, Ishikawa KI, Yamaguchi A, Nojiri S, Akamatsu W, Hattori N. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease. Cells. 2018 Dec 29;8(1).

48. Nishihara K, Shiga T, Nakamura E, Akiyama T, Sasaki T, Suzuki S, Ko M, Tada N, Okano H, Akamatsu W. Induced pluripotent stem cells reprogrammed with three inhibitors show accelerated differentiation potentials and express 2-cell-stage markers. Stem Cell Reports 2019 Feb 12;12(2):305-318.

49.Tsunemi T, Perez-Rosello T, Ishiguro Y, Yoroisaka A, Jeon S, Hamada K, Rammonhan M, Wong YC, Xie Z, Akamatsu W, Mazzulli JR, Surmeier DJ, Hattori N, Krainc D.Increased Lysosomal Exocytosis Induced by Lysosomal Ca 2+ Channel Agonists Protects Human Dopaminergic Neurons From α-Synuclein Toxicity. J Neurosci. 2019 Jul 17;39(29):5760-5772.

50.Kuzumaki N, Suda Y, Iwasawa C, Narita M, Sone T, Watanabe M, Maekawa A, Matsumoto T, Akamatsu W, Igarashi K, Tamura H, Takeshima H, Tawfik VL, Ushijima T, Hattori N, Okano H, Narita M.Cell-specific Overexpression of COMT in Dopaminergic Neurons of Parkinson's Disease. Brain. 2019 Jun 1;142(6):1675-1689.

51.Hirano K, Fujimaki M, Sasazawa Y, Yamaguchi A, Ishikawa KI, Miyamoto K, Souma S, Furuya N, Imamichi Y, Yamada D, Saya H, Akamatsu W, Saiki S, Hattori N. Neuroprotective effects of memantine via enhancement of autophagy.Biochem Biophys Res Commun. 2019 Oct 8;518(1):161-170.

52.Ikeda A, Nishioka K, Meng H, Takanashi M, Hasegawa I, Inoshita T, Shiba-Fukushima K, Li Y, Yoshino H, Mori A, Okuzumi A, Yamaguchi A, Nonaka R, Izawa N, Ishikawa KI, Saiki H, Morita M, Hasegawa M, Hasegawa K, Elahi M, Funayama M, Okano H, Akamatsu W, Imai Y, Hattori N.Mutations in CHCHD2 cause α-synuclein aggregation.Hum Mol Genet. 2019 Dec 1;28(23):3895-3911.

53.Fukunaga I, Shiga T, Chen C, Oe Y, Danzaki K, Ohta S, Matsuoka R, Anzai T, Hibiya-Motegi R, Tajima S, Ikeda K, Akamatsu W, Kamiya K.Generation of the induced pluripotent stem cell (hiPSC) line (JUFMDOi004-A) from a patient with hearing loss carrying GJB2 (p.V37I) mutation. Stem Cell Res. 2020 Mar;43:101674.

54.Kataura T, Saiki S, Ishikawa KI, Akamatsu W, Sasazawa Y, Hattori N, Imoto M.BRUP-1, an intracellular bilirubin modulator, exerts neuroprotective activity in a cellular Parkinson's disease model. J Neurochem. 2020 Mar 3.

55. Oji Y, Hatano T, Ueno SI, Funayama M, Ishikawa KI, Okuzumi A, Noda S, Sato S, Satake W, Toda T, Li Y, Hino-Takai T, Kakuta S, Tsunemi T, Yoshino H, Nishioka K, Hattori T, Mizutani Y, Mutoh T, Yokochi F, Ichinose Y, Koh K, Shindo K, Takiyama Y, Hamaguchi T, Yamada M, Farrer MJ, Uchiyama Y, Akamatsu W, Wu YR, Matsuda J, Hattori N.Variants in saposin D domain of prosaposin gene linked to Parkinson's disease.Brain. 2020 Apr 1;143(4):1190-1205.

56.Popovitchenko T, Park Y, Page NF, Luo X, Krsnik Z, Liu Y, Salamon I, Stephenson JD, Kraushar ML, Volk NL, Patel SM, Wijeratne HRS, Li D, Suthar KS, Wach A, Sun M, Arnold SJ, Akamatsu W, Okano H, Paillard L, Zhang H, Buyske S, Kostovic I, De Rubeis S, Hart RP, Rasin MR.Translational derepression of Elavl4 isoforms at their alternative 5' UTRs determines neuronal development. Nat Commun. 2020 Apr 3;11(1):1674.

57.Shiba-Fukushima K, Inoshita T, Sano O, Iwata H, Ishikawa KI, Okano H, Akamatsu W, Imai Y, Hattori N.A Cell-Based High-Throughput Screening Identified Two Compounds that Enhance PINK1-Parkin Signaling. iScience. 2020 Apr 11;23(5):101048.

58.Yamaguchi A, Ishikawa KI, Inoshita T, Shiba-Fukushima K, Saiki S, Hatano T, Mori A, Oji Y, Okuzumi A, Li Y, Funayama M, Imai Y, Hattori N, Akamatsu W. Identifying Therapeutic Agents for Amelioration of Mitochondrial Clearance Disorder in Neurons of Familial Parkinson Disease. Stem Cell Reports
. 2020 Jun 9;14(6):1060-1075. doi: 10.1016/j.stemcr.2020.04.011.

59.Fukunaga I, Shirai K, Oe Y, Danzaki K, Ohta S, Shiga T, Chen C, Ikeda K, Akamatsu W, Kawano A, Kamiya K. Generation of two induced pluripotent stem cell lines from PBMCs of siblings carrying c.235delC mutation in the GJB2 gene associated with sensorineural hearing loss.Stem Cell Res. 2020 Jul 19;47:101910. doi: 10.1016/j.scr.2020.101910.

60.Tsunemi T, Ishiguro Y, Yoroisaka A, Valdez C, Miyamoto K, Ishikawa K, Saiki S, Akamatsu W, Hattori N, Krainc D. Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation. J Neurosci
. 2020 Nov 4;40(45):8618-8628. doi: 10.1523/JNEUROSCI.0954-20.2020.

61.Kano M, Takanashi M, Oyama G, Yoritaka A, Hatano T, Shiba-Fukushima K, Nagai M, Nishiyama K, Hasegawa K, Inoshita T, Ishikawa KI, Akamatsu W, Imai Y, Bolognin S, Schwamborn JC, Hattori N. Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations. NPJ Parkinsons Dis
. 2020 Nov 13;6(1):33. doi: 10.1038/s41531-020-00137-8.

62.Yokota M, Kakuta S, Shiga T, Ishikawa KI, Okano H, Hattori N, Akamatsu W, Koike M. Establishment of an in vitro model for analyzing mitochondrial ultrastructure in PRKN-mutated patient iPSC-derived dopaminergic neurons. Mol Brain. 2021 Mar 23;14(1):58. doi: 10.1186/s13041-021-00771-0.

63.Fukunaga I, Oe Y, Danzaki K, Ohta S, Chen C, Iizumi M, Shiga T, Matsuoka R, Anzai T, Hibiya-Motegi R, Tajima S, Ikeda K, Akamatsu W, Kamiya K. Generation of two iPSC lines from siblings of a homozygous patient with hearing loss and a heterozygous carrier with normal hearing carrying p.G45E/Y136X mutation in GJB2. Stem Cell Res. 2021 May;53:102290. doi: 10.1016/j.scr.2021.102290.

64.Nakai K, Shiga T, Yasuhara R, Sarkar AK, Abe Y, Nakamura S, Hoashi Y, Kotani K, Tatsumoto S, Ishikawa H, Go Y, Inoue T, Mishima K, Akamatsu W, Baba K.In vitro monitoring of HTR2A-positive neurons derived from human-induced pluripotent stem cells. Sci Rep. 2021 Jul 29;11(1):15437. doi: 10.1038/s41598-021-95041-3.

65.Toritsuka M, Yoshino H, Makinodan M, Ikawa D, Kimoto S, Yamamuro K, Okamura K, Akamatsu W, Okada Y, Matsumoto T, Hashimoto K, Ogawa Y, Saito Y, Watanabe K, Aoki C, Takada R, Fukami SI, Hamano-Iwasa K, Okano H, Kishimoto T. Developmental dysregulation of excitatory-to-inhibitory GABA-polarity switch may underlie schizophrenia pathology: A monozygotic-twin discordant case analysis in human iPS cell-derived neurons. Neurochem Int. 2021 Nov;150:105179.

66.Yamaguchi A, Ishikawa KI, Akamatsu W. Methods to Induce Small-Scale Differentiation of iPS Cells into Dopaminergic Neurons and to Detect Disease Phenotypes. Methods Mol Biol. 2022;2549:271-279.

67.Ishikawa KI, Ishiguro M, Li Y, Nishioka K, Hattori N, Akamatsu W. Generation of three hiPSC clones from a Parkinson's disease patient with a heterozygous variant of VPS35 p.D620N. Stem Cell Res. 2022 Jan 3;59:102658.

68.Miyamoto K, Saiki S, Matsumoto H, Suzuki A, Yamashita Y, Iseki T, Ueno SI, Shiina K, Kataura T, Kamagata K, Imamichi Y, Sasazawa Y, Fujimaki M, Akamatsu W, Hattori N. Systemic Metabolic Alteration Dependent on the Thyroid-Liver Axis in Early PD. Ann Neurol. 2022 Sep 21. doi: 10.1002/ana.26510.

69.Sasaki R, Kurebayashi N, Eguchi H, Horimoto Y, Shiga T, Miyazaki S, Kashiyama T, Akamatsu W, Saito M. Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity Cancer Sci. 2022 Oct;113(10):3449-3462.

70.Ukaji T, Takahashi-Shibata M, Arai D, Tsutsumi H, Tajima S, Akamatsu W, Matsumoto F, Ikeda K, Usami SI, Kamiya K. Generation and characterization of a human iPSC line (JUFMDOi007-A) from a patient with Usher syndrome due to mutation in USH2A Stem Cell Res. 2023 Jun;69:103100. doi: 10.1016/j.scr.2023.103100.

71.Nakamura R, Nonaka R, Oyama G, Jo T, Kamo H, Nuermaimaiti M, Akamatsu W, Ishikawa KI, Hattori N. A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson's disease.Front Neurosci. 2023 Jul 12;17:1202027. doi: 10.3389/fnins.2023.1202027. eCollection 2023.

72.Torii S, Arakawa S, Sato S, Ishikawa KI, Taniguchi D, Sakurai HT, Honda S, Hiraoka Y, Ono M, Akamatsu W, Hattori N, Shimizu S.Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2.EMBO Mol Med. 2023 Aug 14:e17451. doi: 10.15252/emmm.202317451.

73. Yokota M, Yoshino Y, Hosoi M, Hashimoto R, Kakuta S, Shiga T, Ishikawa KI, Okano H, Hattori N, Akamatsu W, Koike M. Reduced ER-mitochondrial contact sites and mitochondrial Ca2+ flux in PRKN-mutant patient tyrosine hydroxylase reporter iPSC lines. Front Cell Dev Biol. 2023 Sep 8;11:1171440. doi: 10.3389/fcell.2023.1171440. eCollection 2023.

74. Daida K, Funayama M, Billingsley KJ, Malik L, Miano-Burkhardt A, Leonard HL, Makarious MB, Iwaki H, Ding J, Gibbs JR, Ishiguro M, Yoshino H, Ogaki K, Oyama G, Nishioka K, Nonaka R, Akamatsu W, Blauwendraat C, Hattori N. Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease. Mov Disord. 2023 Dec;38(12):2249-2257.

75. Ishikawa KI, Shiga T, Funayama M, Hattori N, Akamatsu W. Generation of a control iPS cell line (JUCGRMi005-A) with no abnormalities in Parkinson's disease-related genes. Stem Cell Res. 2024 Feb:74:103271.

76. Ishikawa KI, Shiga T, Funayama M, Hattori N, Akamatsu W. Generation of a control iPS cell line (JUCGRMi006-A) with no abnormalities in Parkinson's disease-related genes. Stem Cell Res. 2024 Feb:74:103270.

77. Liu L, Yang J, Otani Y, Shiga T, Yamaguchi A, Oda Y, Hattori M, Goto T, Ishibashi S, Kawashima-Sonoyama Y, Ishihara T, Matsuzaki Y, Akamatsu W, Fujitani M, Taketani T. MELAS-Derived Neurons Functionally Improve by Mitochondrial Transfer from Highly Purified Mesenchymal Stem Cells (REC) Int J Mol Sci 2023 Dec 6;24(24):17186. doi: 10.3390/ijms242417186.

78. Ishikawa KI, Shiga T, Yoshino H, Nishioka K, Hattori N, Akamatsu W. Generation of three clones (JUCGRMi002-A, B, C) of induced pluripotent stem cells from a Parkinson's disease patient with SNCA duplication. Stem Cell Res. 2024 Feb;74:103296.

79. Ishikawa KI, Okuzumi A, Yoshino H, Hattori N, Akamatsu W. Generation of hiPSCs (JUCGRMi003-A) from a patient with Parkinson's disease with PARK2 mutation Stem Cell Res 2024 Apr:76:103323. doi: 10.1016/j.scr.2024.103323. Epub 2024 Jan 30.

80.Liu X, Ishikawa KI, Hattori N, Akamatsu W. Generation of one induced pluripotent stem cell line JUCGRMi004-A from a Charcot-Marie-Tooth disease type 1A (CMT1A) patient with PMP22 duplication Stem Cell Res
. 2024 Jun:77:103401. doi: 10.1016/j.scr.2024.103401. Epub 2024 Mar 24.

81.Hori A, Inaba H, Hato T, Tanaka K, Sato S, Okamoto M, Horiuchi Y, Paran FJ, Tabe Y, Mori S, Rosales C, Akamatsu W, Murayama T, Kurebayashi N, Sakurai T, Ai T, Miida T. Carvedilol suppresses ryanodine receptor-dependent Ca2+ bursts in human neurons bearing PSEN1 variants found in early onset Alzheimer's disease PLoS One. 2024 Aug 22;19(8):e0291887. doi: 10.1371/journal.pone.0291887. eCollection 2024.

82.Arai D, Takahashi-Shibata M, Ukaji T, Tsutsumi H, Tajima S, Nishio SY, Ishikawa KI, Akamatsu W, Matsumoto F, Ikeda K, Usami SI, Kamiya K. Generation of an induced pluripotent stem cell line from a late-onset, progressive high frequency hearing loss patient due to mutation in CDH23 Stem Cell Res. 2024 Sep;79:103471. doi: 10.1016/j.scr.2024.103471. Epub 2024 Jun 12.

・和文総説
1) 岡野　栄之, 榊原　伸一, 今井　貴雄, 赤松　和土神経発生の新しい制御因子の発見とその臨床応用への試み：脳の科学　20: 665-670 1998

2) 赤松　和土, 岡野　栄之：神経特異的RNA結合蛋白質による神経発生の制御.　蛋白質・核酸・酵素　: 45(3) 19-24 ,2000

3) 赤松　和土, 岡野　栄之：神経幹細胞の分化制御機構と再生医学への応用：医学のあゆみ　: 192(8) 843-846 ,2000

4) 赤松　和土, 岡野　栄之：神経幹細胞の分化制御機構と再生医学への応用」：臨床リハビリテーション :2000 9:811

5) 赤松　和土, 岡野　栄之：神経幹細胞とその神経疾患治療への応用：脳と発達: 2001 33;114-120

6) 赤松　和土：神経特異的RNA結合蛋白質による神経発生の制御：小児科診療　2001,64(12);2228-2229

7) 赤松　和土：神経幹細胞とその神経疾患治療への応用：小児科: 42(13);2039-2045　2001

8) 今井貴雄，岡部正隆，赤松和土，岡野ジェイムス洋尚，岡野栄之: 神経分化を制御する神経系特異的RNA結合蛋白質: 生体の科学 V.53/No.2/P.84-90 ; 2002

9) 松井　健, 赤松　和土, 岡野栄之: 神経を創る─ Direct conversion による神経系細胞の誘導と医薬応用, in vivo実験医学によるヒト疾患解明の最前線実験医学増刊号 30(2) 43-50, 2012

10) 赤松　和土：疾患特異的iPS細胞研究の基礎と実際：バイオクリニカ　28(3) 22-26　2013

11) 赤松　和土：神経系のiPS technologyの今後の展望：神経内科検査のみかた−脳のイメージングを中心に：モダンフィジシャン　33(5) 696-698 2013

12) 赤松　和土：神経幹細胞の分化誘導・直接誘導実験医学増刊　Vol.33 No.2
再生医療2015 幹細胞と疾患iPS細胞の研究最前線

13) 赤松　和土：線維芽細胞→神経幹細胞　細胞工学別冊『ダイレクトリプログラミング』2015

14) 赤松　和土：体細胞からの神経系細胞の直接誘導　日本臨床　2015　増刊号　

15) 石川景一、服部信孝、赤松和土: 疾患モデル細胞, iPS細胞を用いた毒性評価と創薬研究, iPS細胞を用いたパーキンソン病の病態解析日本臨牀　2015年6月増刊号

16) 赤松　和土：疾患特異的iPS細胞を用いた神経疾患研究：実験医学　34: 524-233, 2016

17) 赤松　和土：iPS細胞を用いた神経・精神疾患の研究：分子精神医学　16: 227-233, 2016

18) 赤松　和土：ヒト多能性幹細胞から脳・脊髄の任意領域のニューロンへの誘導技術：医学のあゆみ　259: 1148-1149, 2016.12.10

19) 赤松　和土：iPS細胞を用いた難病研究：LiSA　26(7): 687-694, 2019

20) 赤松　和土：iPS細胞を用いた神経疾患と創薬：月刊　腎臓内科　12（3）: 1−8, 2020

21) 赤松　和土：iPS細胞を用いたパーキンソン病の病態解析：生体の科学　73（5）: 484−485, 2022

22) 赤松　和土：iPS細胞を用いたパーキンソン病の病態解明と創薬：心身医学　63: 317−320, 2023

23) 赤松　和土：パーキンソン病の病態解明と創薬：分子精神医学　50（2）: 71−74, 2024

（英文総説）
1. Matsui T, Akamatsu W, Nakamura M, Okano H. Regeneration of the damaged central nervous system through reprogramming technology: Basic concepts and potential application for cell replacement therapy. Exp Neurol. 2012 Oct 1. doi:pii: S0014-4886(12)00378-0. 10.1016/j.expneurol.2012.09.016.

2. Andoh-Noda T, Inouye MO, Miyake K, Kubota T, Okano H, Akamatsu W. Modeling Rett Syndrome Using Human Induced Pluripotent Stem Cells. CNS Neurol Disord Drug Targets. 15:544-50. 2016

（英文著書）
1. The regulatory mechanisms of Neural Development: Roles of Cell-autonomous Cues in Cell-Fate Decisions. Keio University Symposia for LifeScience and Medicine, Vol2 Neural Development. Okano H., Kaneko Y., Nakamura Y., Akamatsu W., Yuasa Y., Imai T., Hirota Y., Jin MH., Tabuchi K., Taguchi A., Okabe M., Sakakibara S., Goto T., Uchiyama Y and Sawamoto K.：Springer-Verlag Tokyo 9-23,1999

2. Functions of neural RNA-binding proteins Musashi and Hu in stem cells and neuronal differentiation. RNA Binding Proteins in Development and Disease: Kawahara H, Yano M, Imai T, Akamatsu W, Okano HJ, Okano H: Research Signpost, 2007

3. Imamura M, Okuno H, Tomioka I, Kawamura Y, Lin ZY, Nakajima R, Akamatsu W, Okano HJ, Matsuzaki Y, Sasaki E, Okano H： Derivation of induced pluripotent stem cells by retroviral gene transduction in mammalian species. Methods Mol Biol. 925: 21-48. 2012

4. Ohta S, Imaizumi Y, Akamatsu W, Okano H, Kawakami Y: Generation of human melanocytes from induced pluripotent stem cells. Methods Mol Biol. 989: 193-215. 2013,

5. Direct Induction of Neural Stem Cells from Somatic Cells. Akamatsu W, Okano H. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease, Fifth Edition 2014

6. Ishikawa KI, Yamaguchi A, Okano H, Akamatsu W. Assessment of Mitophagy in iPS Cell-Derived Neurons. Methods Mol Biol. 2017 Mar 22. [Epub ahead of print] ,

7. Yamaguchi A, Ishikawa KI, Akamatsu W. Methods to Induce Small-Scale Differentiation of iPS Cells into Dopaminergic Neurons and to Detect Disease Phenotypes. Methods Mol Biol. 2021 Mar 24. doi: 10.1007/7651_2021_376.

8. Ishikawa KI, Nonaka R, Akamatsu W. Differentiation of Midbrain Dopaminergic Neurons from Human iPS Cells. Methods Mol Biol. 2021;2322:73-80. doi: 10.1007/978-1-0716-1495-2_8.

（和文著書）
1. 赤松和土、岡野栄之「神経系におけるRNA結合蛋白質を介した遺伝子発現調節機構」 RNAがわかる;羊土社　東京　125-130　2003

2. 赤松和土、岡野栄之「神経幹細胞とその神経疾患治療への応用」疾患モデル動物文光堂東京 2004

(アウトリーチ活動)
1. 赤松和土　「iPS細胞を使って神経系の病気に苦しむ患者さんを助けられるか？」　順天堂大学医学部　基礎研究医養成プログラム主催　高校生のための夏休み医学教室：研究医とのサイエンストーク2016.7.26
2. 赤松和土「iPS細胞を用いたパーキンソン病の病態研究と治療法開発」　
「患者・社会と考える再生医療」～「再生医療の研究をめぐる情報」について、みんなで考えてみませんか？～日本再生医療学会イベント（大阪）　2018.1.28
3. 赤松和土「iPS細胞を使って脳の病気を再現する—病気の仕組みの解明と新しい薬の開発—」　順天堂大学第41回都民公開講座「再生医療の現状」　2018.2.17

(プレスリリース)
1.2016年2月19日順天堂大学
ヒトiPS 細胞の高効率な神経分化誘導方法の開発とパーキンソン病iPS細胞バンクの構築へ　～パーキンソン病の病態研究・再生医療を促進～

2.2017年10月27日順天堂大学
3つの小分子化合物を用いてヒトiPS細胞の分化能力を促進する基盤技術を開発～～病態モデルにおける分化成熟・老化を促進、iPS細胞株選別を不要に～

3. 2019年2月1日順天堂大学
3つの化合物を用いてiPS細胞の分化成熟能力を高める技術を開発～成熟した細胞への分化誘導期間を短縮～

4. 2020年5月29日順天堂大学
パーキンソン病の病態を改善させる治療薬探索システムを確立
～患者由来iPS細胞を用いた薬剤スクリーニングシステム～

研究者

教育活動

ホームページURL

【学校法人順天堂】研究者情報データベース

研究業績詳細

赤松 和土（アカマツ ワド）

赤松和土（アカマツワド）